Market News
Sun Pharma, Laurus Labs, Mankind Pharma, others drag Nifty Pharma down 1.6%; here’s what investors should know
4 min read | Updated on September 01, 2026, 13:39 IST
SUMMARY
Nifty Pharma index declined 1.62% on Tuesday, September 1, amid the wider weakness in equities and selling pressure on heavyweight pharma stocks, which dragged down the benchmark index.
Nifty Pharma index declined 1.62% to 26,745.20 points during the intraday trading session on Tuesday, September 1. | Image: Shutterstock
Pharmaceutical sector companies like Sun Pharma, Laurus Labs, Mankind Pharma, and Divi’s Laboratories, among several other heavyweight stocks dragged down the sectoral benchmark Nifty Pharma index on Tuesday, September 1, due to selling pressure from investors and capital rotation amid elevated oil prices.
NSE data showed that the Nifty Pharma index declined 1.62% to 26,745.20 points during the intraday trading session on Tuesday, in comparison to 27,186.45 points at the previous equity market close.
Investors were also focused on several stock-specific announcements in the pharma sector, along with the subdued momentum spillover from the Indian healthcare sector, which impacted hospital and healthcare service stocks on Tuesday’s market.
With rising US Treasury yields and a 7-day high in crude oil prices in the global market, the overall sentiment of equities was dented on September 1, amid the escalating tensions in West Asia and the pricing of drugs in the US markets.
The selling pressure in the pharma sector also emerged due to Sun Pharma’s latest announcement around the company’s US drug pricing deal, which seeks to deliver affordable medicines for millions of American patients.
Indian pharma companies are largely export-dependent, with the United States being a major client for exports and with supply chain disruptions in West Asia, supply-side risk still remains high in the market.
Pharma stocks in focus today
| Company name | Current price | Intraday returns | 5-day returns | 1-month returns |
|---|---|---|---|---|
| Laurus Labs | ₹1,884 | -4% | -1.1% | 1.5% |
| Divi’s Laboratories | ₹9,156 | -3.7% | 4.7% | 13.6% |
| Mankind Pharma | ₹2,354 | -2.8% | -0.4% | -4.6% |
| Sun Pharma | ₹1,936 | -2.7% | 0.7% | -2.7% |
| Biocon | ₹403 | -2.4% | -3.4% | -5.3% |
| Torrent Pharma | ₹4,966 | -2.8% | 0.7% | -3% |
| Ajanta Pharma | ₹3,500 | -3.2% | -1.5% | 0.9% |
| Lupin | ₹2,154 | -1.6% | -0.9% | -10.8% |
| Aurobindo Pharma | ₹1,693 | -2.4% | 4.6% | 7.1% |
| Wockhardt | ₹1,846 | -1.5% | -1.9% | -4.9% |
Latest updates investors should know
On September 1, India’s largest pharmaceutical company, Sun Pharmaceutical, said that the firm joined several other companies at a White House ceremony to announce agreements with the US government that aim to prioritise access to affordable medicines for millions of patients.
As part of the deal, Sun Pharma will extend Most Favoured Nation (MFN) pricing to state Medicaid programs and, in exchange, the US import tariffs on the company’s products have been delayed for the next two years, under Section 232.
United States remains Sun Pharma’s largest market for innovative medicines, generating approximately 27% of the company’s global revenue.
Another major announcement was from Mankind Pharma, which sold a 100% stake in Broadway Hospitality Services to AKRK Projects LLP, which has resulted in the company ceasing to be a wholly-owned subsidiary effective August 31.
This divestment move was for a total consideration of ₹49 crore, as per the exchange filing.
Experts from global investment firm HSBC said that Aurobindo Pharma’s subsidiary, Lannett, launching a generic version of Advair Diskus is a significant launch for the company in view of the sizeable addressable market and limited competition.
“The addressable market for Advair Diskus (including its generic equivalents) in US is over $650 million, per co. There are currently five approved generics for Advair Diskus – Viatris, Hikma, Teva, Lannett and Cipla,” said the analysts.
Related News
About The Author
Next Story
